Sarcoma after 5 years of progression‐free survival: Lessons from the French Sarcoma Group

E-ISSN： 1097-0142|120|19|2942-2943

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.19, 2014-10, pp. : 2942-2943

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Because sarcomas are rare (1% of all adult solid malignancies) and encompass a heterogeneous group of tumors (> 50 subtypes), information regarding late recurrences for patients with resected soft tissue sarcomas, although recognized to occur, is not well defined. Details concerning late recurrences, such as the frequencies, risk factors, and relative rates between tumor subtypes, depend on the existence of a large, well‐annotated, multiinstitutional, accurate database that spans several decades of clinical experience. The French Sarcoma Group has assembled such a database, and they report with accuracy and detail what happens to patients with sarcoma after they survive for > 5 years. Recognition that a significant percentage of long‐term survivors of sarcoma are still at risk of developing late disease recurrence can be paired with the growing awareness that they are also at risk of a shortened lifespan and increased cardiovascular and psychological morbidity to highlight a critical role for long‐term specialty follow‐up.